ReviewPathology2019
Ductal carcinoma in situ of breast: update 2019.
Review in Pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Recurrence Patterns and Overtreatment in Pure DCIS: A Retrospective Clinical and Radiological Follow-Up Study.Journal of personalized medicine · 2026Article
- Fear of diagnosis as a barrier to the screening and diagnosis of breast cancer.Breast cancer (Tokyo, Japan) · 2026Article
- Fast multimodal imaging combined with machine learning identifying taurine as a potential marker for breast cancer margin assessment.NPJ digital medicine · 2025Article
- Prediction of intraductal cancer microinfiltration based on the hierarchical fusion of peri-tumor imaging histology and dual view deep learning.BMC cancer · 2025Article
- Prediction of upstaging in DCIS: the dominant role of pathological over imaging risk factors.Breast cancer research and treatment · 2025Article
- Epigenetic regulation of breast ductal carcinoma in situ by miR-217 through DNMT1 and Hedgehog-GLI pathway.Journal of cell communication and signaling · 2025Article
- The DCIS-IBC guide board on predicting postoperative upgrading in breast ductal carcinoma in situ: clinical insights from a multicenter study.Breast cancer research and treatment · 2025Article
- Can Mammography and Magnetic Resonance Imaging Predict the Preoperative Size and Nuclear Grade of Pure Ductal Carcinoma In Situ?Diagnostics (Basel, Switzerland) · 2025Article
- Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.JAMA oncology · 2025Article
- Nanostructured Formulations for a Local Treatment of Cancer: A Mini Review About Challenges and Possibilities.Pharmaceutics · 2025Review
- Case Report: Sneaky DCIS-like invasive ductal carcinoma of the breast in the setting of extensive DCIS.Frontiers in medicine · 2025Article
- Changes to the US Preventive Services Task Force Screening Guidelines and Incidence of Breast Cancer.JAMA network open · 2024Article
- Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast.Breast cancer research and treatment · 2024Review
- Comparison of locoregional recurrence risk among nipple-sparing mastectomy, skin-sparing mastectomy, and simple mastectomy in patients with ductal carcinoma in situ: a single-center study.Breast cancer (Tokyo, Japan) · 2024Article
- Upper Extremity Deep Vein Thrombosis in the Setting of Ductal Carcinoma In Situ: A Case Report.Cureus · 2024Article
- Tumor microenvironmental determinants of high-risk DCIS progression.Research square · 2024Article
- Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.Signal transduction and targeted therapy · 2024Review
- Male ductal carcinoma in situ: diagnosis and management of a rare disease in men.BMJ case reports · 2024Article
- Age and race/ethnicity differences in decisional conflict in women diagnosed with ductal carcinoma in situ.BMC women's health · 2024Article
- Comparison of the effectiveness of contrast-enhanced mammography in detecting malignant lesions in patients with extremely dense breasts compared to the all-densities population.Polish journal of radiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Ductal carcinoma in situ is a non-invasive form of breast cancer. Its incidence is increasing due to widespread use of mammographic screening. It presents several diagnostic and management challenges in part due to its relatively indolent behaviour. Most series analysing biomarkers in these lesions are small (<100 patients) and large clinical trials have not been frequent. Herein, we review the recent progress made in understanding the biology of this entity and the tools available for prognostication.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.